IDRA

Idera Pharmaceuticals, Inc. Press Releases

$4.87
*  
0.27
5.25%
Get IDRA Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading IDRA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Idera to Present at Two Upcoming Investor Healthcare Conferences
2/23/2015 12:00:00 PM - GlobeNewswire


Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock
2/19/2015 3:21:00 PM - GlobeNewswire


Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2/13/2015 8:30:00 AM - GlobeNewswire


Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2/9/2015 4:01:00 PM - GlobeNewswire


Idera Announces Leadership Appointments
1/26/2015 4:30:00 PM - GlobeNewswire


Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/9/2015 1:00:00 PM - GlobeNewswire


eFuture Announces Voting Results of Its 2014 Annual General Meeting
12/30/2014 8:00:00 AM - GlobeNewswire


Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom''s Macroglobulinemia
12/30/2014 8:00:00 AM - GlobeNewswire


Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
12/15/2014 9:00:00 AM - GlobeNewswire


Idera Announces Several Key Additions to Management Team
12/15/2014 9:00:00 AM - GlobeNewswire


Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
12/8/2014 5:45:00 PM - GlobeNewswire


Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
12/2/2014 4:30:00 PM - GlobeNewswire


Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications
12/2/2014 10:12:00 AM - GlobeNewswire


Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
12/2/2014 8:30:00 AM - GlobeNewswire


Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
12/1/2014 4:30:00 PM - GlobeNewswire